Jiangsu Vcare Pharmatech Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Jiangsu Vcare Pharmatech Co., Ltd. - overview
Established
2010
Location
Nanjing, Jiangsu, China
Primary Industry
Pharmaceuticals
About
Established in 2010 and based in Nanjing, China, Jiangsu Vcare Pharmatech Co. , Ltd. operates as a pharmaceutical technology company that focuses on the research and development of chemical drugs. It was recognized as the National High-tech Enterprise.
The company has a production base in Xiangyang. In 2017, the company completed the acquisition of the Nantong API plant. There are more than 500 employees in the company. Vcare Pharmatech has applied for 89 domestic and foreign invention patents, including 11 PCT (Patent Cooperation Treaty) patents.
In January 2024, it raised over CNY 200 million in series C+ funding. The company mainly provides Generic drugs, APIs (Active Pharmaceutical Ingredient), impurities in APIs, other intermediates. Its main products include VC004, Vicagrere capsules and VC005. VC004 is a class 1 targeted antitumor drug and belongs to the second generation of Trk (tropomyosin receptor kinase) inhibitors.
Vcare Pharmatech has established targeted innovation development platform, computer-aided drug design platform, drug synthesis and separation technology platform. The company also provides pharmaceutical services, clinical services, chemistry CDMO (contract development and manufacturing organization) services. The company's drug research and development pipelines cover the fields of cardiovascular, cerebrovascular, tumour, endocrine. The company generates revenue by providing innovative drugs.
The company will use the series C funding to advance the clinical pipeline of innovative drugs and the industrial chain layout of CRO and CDMO services.
Current Investors
China Merchants Capital, Fengling Capital, Jadestone Capital
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.vcarepharmatech.com
Verticals
Manufacturing
Company Stage
Series C
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.